Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis

被引：14

作者：

Roviello, Giandomenico ^{[1
,2
]}

Pacifico, Chiara ^{[3
]}

Corona, Paola ^{[4
]}

Generali, Daniele ^{[2
,5
]}

机构：

[1] San Donato Hosp, Dept Oncol, Med Oncol Unit, Via Nenni 20, I-52100 Arezzo, Italy

[2] Univ Trieste, Dept Med Surg & Hlth Sci, Piazza Ospitale 1, I-34129 Trieste, Italy

[3] Univ Hosp Siena, Unit Raiotherapy, Dept Med Surg & Neurol Sci, Siena, Italy

[4] Peter MacCallum Canc Ctr, Radiat Oncol Dept, Moorabbin Campus, East Bentleigh, Vic 3165, Australia

[5] ASST Cremona, Unit Mol Therapy & Pharmacogen, Viale Concordia 1, I-26100 Cremona, Italy

来源：

INVESTIGATIONAL NEW DRUGS | 2017年 / 35卷 / 04期

关键词：

Ramucirumab; Hypertension; Solid tumors; Gastric cancer; CELL LUNG-CANCER; DOUBLE-BLIND; GASTROESOPHAGEAL JUNCTION; PHASE-II; DISEASE PROGRESSION; COLORECTAL-CANCER; 1ST-LINE THERAPY; PLACEBO; MULTICENTER; ADENOCARCINOMA;

D O I：

10.1007/s10637-017-0452-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse events associated with ramucirumab therapy. Recent studies looked at the quantification of the risk of hypertension in patients receiving other anti-angiogenesis medications. We conducted a meta-analysis of randomized clinical trials with the aim to investigate the incidence and quantify the risk of new-onset hypertension of any grade in patients treated with ramucirumab. Our research suggests that hypertension is frequently associated with ramucirumab therapy, with an OR of 3.60 for any grade of hypertension and an even stronger correlation with grade 3-4 hypertension (OR 4.16). These data suggest that a strict monitoring, as well as early intervention protocols, are recommended in patients receiving the drug.

引用

页码：518 / 523

页数：6

共 20 条

[1]

Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials [J].

Chen, Jian ;

Lu, Yingfeng ;

Zheng, Yunliang .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :4751-4760

[2]

THE COMBINATION OF ESTIMATES FROM DIFFERENT EXPERIMENTS [J].

COCHRAN, WG .

BIOMETRICS, 1954, 10 (01) :101-129

[3]

METAANALYSIS IN CLINICAL-TRIALS [J].

DERSIMONIAN, R ;

LAIRD, N .

CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188

[4]

Association between bevacizumabrelated hypertension and response to treatment in patients with metastatic colorectal cancer [J].

Dionisio de Sousa, Isabel Jose ;

Ferreira, Joana ;

Rodrigues, Joana ;

Bonito, Nuno ;

Jacinto, Paula ;

Marques, Mariela ;

Ribeiro, Joao ;

Pais, Ana ;

Gervasio, Helena .

ESMO OPEN, 2016, 1 (03)

[5]

The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

[6]

Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study [J].

Fraeman, Kathy H. ;

Nordstrom, Beth L. ;

Luo, Weixiu ;

Landis, Sarah H. ;

Shantakumar, Sumitra .

INTERNATIONAL JOURNAL OF HYPERTENSION, 2013, 2013

[7]

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].

Fuchs, Charles S. ;

Tomasek, Jiri ;

Yong, Cho Jae ;

Dumitru, Filip ;

Passalacqua, Rodolfo ;

Goswami, Chanchal ;

Safran, Howard ;

dos Santos, Lucas Vieira ;

Aprile, Giuseppe ;

Ferry, David R. ;

Melichar, Bohuslav ;

Tehfe, Mustapha ;

Topuzov, Eldar ;

Zalcberg, John Raymond ;

Chau, Ian ;

Campbell, William ;

Sivanandan, Choondal ;

Pikiel, Joanna ;

Koshiji, Minori ;

Hsu, Yanzhi ;

Liepa, Astra M. ;

Gao, Ling ;

Schwartz, Jonathan D. ;

Tabernero, Josep .

LANCET, 2014, 383 (9911) :31-39

[8]

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].

Garon, Edward B. ;

Ciuleanu, Tudor-Eliade ;

Arrieta, Oscar ;

Prabhash, Kumar ;

Syrigos, Konstantinos N. ;

Goksel, Tuncay ;

Park, Keunchil ;

Gorbunova, Vera ;

Dario Kowalyszyn, Ruben ;

Pikiel, Joanna ;

Czyzewicz, Grzegorz ;

Orlov, Sergey V. ;

Lewanski, Conrad R. ;

Thomas, Michael ;

Bidoli, Paolo ;

Dakhil, Shaker ;

Gans, Steven ;

Kim, Joo-Hang ;

Grigorescu, Alexandru ;

Karaseva, Nina ;

Reck, Martin ;

Cappuzzo, Federico ;

Alexandris, Ekaterine ;

Sashegyi, Andreas ;

Yurasov, Sergey ;

Perol, Maurice .

LANCET, 2014, 384 (9944) :665-673

[9]

Measuring inconsistency in meta-analyses [J].

Higgins, JPT ;

Thompson, SG ;

Deeks, JJ ;

Altman, DG .

BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560

[10]

Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J].

Jadad, AR ;

Moore, RA ;

Carroll, D ;

Jenkinson, C ;

Reynolds, DJM ;

Gavaghan, DJ ;

McQuay, HJ .

CONTROLLED CLINICAL TRIALS, 1996, 17 (01) :1-12

← 1 2 →